Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
| Autor: | Ramon K. Kemp, Marian Iwamoto, Joshua Chen, Steven D. Young, Hedy Teppler, Robert A. Fromtling, Randi Y. Leavitt, Wei Xu, Robin Isaacs, Michael D. Miller, Daria J. Hazuda, Joseph P. Vacca, Bach-Yen Nguyen, Keith Gottesdiener, Michael W. Lower, Larissa Wenning, Michael Rowley, Peter Sklar |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
business.industry
General Neuroscience Human immunodeficiency virus (HIV) Integrase inhibitor Drug interaction medicine.disease Raltegravir medicine.disease_cause Virology General Biochemistry Genetics and Molecular Biology Virus Raltegravir Potassium Clinical trial History and Philosophy of Science Acquired immunodeficiency syndrome (AIDS) Medicine business medicine.drug |
| Zdroj: | Annals of the New York Academy of Sciences. 1222:83-89 |
| ISSN: | 0077-8923 |
| DOI: | 10.1111/j.1749-6632.2011.05972.x |
| Popis: | Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment-naive as well as heavily pretreated HIV-infected patients failing therapy with multidrug-resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow-up in three phase III studies, protocol 021 (STARTMRK) in treatment-naive patients, and protocols 018 (BENCHMRK-1) and 019 (BENCHMRK-2) in treatment-experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long-term safety profile of raltegravir in both treatment-naive and treatment-experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |